Author

J. Sun

Institution: TYK Medicines, Inc.

Observed institutions: BeiGene (China), TYK Medicines, Inc.

OpenAlex ID: A5031894854

EP08.01-071 Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Non-Squamous NSCLC

2022 · J. Zhao, J. Wu, et al. · Journal of Thoracic Oncology · 1

EP08.01-070 Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Squamous NSCLC

2022 · J. Zhao, J. Cui, et al. · Journal of Thoracic Oncology · 1

505P Safety and preliminary efficacy of a novel CDK2/4 inhibitor TYK-00540 in patients with advanced solid tumors: Results from a phase I dose-escalation study

2025 · Y. Meng, X. Han, et al. · Annals of Oncology

Works count: 3

Citation count: 2

H-index: 1

I10-index: